CHEK2 gene in metastatic prostate cancer: A cordial check on DNA damage repair pathway

Mutation in homologous recombination repair (HRR) pathway is well established ovarian cancers. Multiple trials have shown variable efficacy prostate Mutations other than BRCA1/BRCA2 been recently reported We describe a unique case of an elderly male with metastatic castration-resistant cancer. He responded to hormonal therapy for 6 months but later progressed. Chemotherapy docetaxel produced severe side effects the patient and, thus, was discontinued. Next-generation sequencing performed on tissue sample which selected pathogenic mutation (TIER 1) CHEK2 gene, missense mutation, leading loss function protein. cell cycle regulator and tumor suppressor gene mediating recombinant DNA genetic alterations it makes susceptible newer targeted therapies.